These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25231890)

  • 1. Expanded umbilical cord blood T cells used as donor lymphocyte infusions after umbilical cord blood transplantation.
    Berglund S; Gertow J; Uhlin M; Mattsson J
    Cytotherapy; 2014 Nov; 16(11):1528-1536. PubMed ID: 25231890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
    Chang YJ; Huang XJ
    Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model.
    Li ZY; Wang CQ; Lu G; Pan XY; Xu KL
    Cell Biochem Biophys; 2014 Sep; 70(1):115-22. PubMed ID: 24696072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical Cord Blood Transplantation Is a Feasible Rescue Therapeutic Option for Patients Suffering from Graft Failure after Previous Hematopoietic Stem Cell Transplantation.
    Bojic M; Worel N; Sperr WR; Schellongowski P; Wohlfarth P; Schwarzinger I; Mitterbauer-Hohendanner G; Fischer G; Dieckmann KU; Lamm W; Leiner M; Schulenburg A; Mitterbauer M; Greinix HT; Kalhs P; Rabitsch W
    Oncology; 2016; 90(3):160-6. PubMed ID: 26871562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
    Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
    Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.
    Baron F; Ruggeri A; Nagler A
    Expert Rev Hematol; 2016 Mar; 9(3):297-314. PubMed ID: 26635058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
    Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
    Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Umbilical cord blood as a source of stem cells].
    Bojanić I; Golubić Cepulić B
    Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in umbilical cord blood cell therapy: the present and the future.
    Berglund S; Magalhaes I; Gaballa A; Vanherberghen B; Uhlin M
    Expert Opin Biol Ther; 2017 Jun; 17(6):691-699. PubMed ID: 28379044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
    Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
    Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
    Horn B; Petrovic A; Wahlstrom J; Dvorak CC; Kong D; Hwang J; Expose-Spencer J; Gates M; Cowan MJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):729-37. PubMed ID: 25644958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.